The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics.
Open accessAbstract
The platelet glycoprotein GPIIb/IIIa ( ␣ IIb  3 ) antagonist c7E3 Fab (the Fab fragment of the mouse/human chimeric monoclonal antibody 7E3; abciximab; ReoPro™) was approved for human use in the United States in December 1994 based on its safety and its efficacy in reducing the risk of ischemic complications after percutaneous coronary intervention (PCI; 1 angioplasty or atherectomy) (1, 2).The success of this agent reflects our emerging ability to identify adhesion molecules as therapeutic targets, and then construct effective inhibitors that meet the stringent safety standards required for a new drug.As the first rationally designed antiplatelet and anti-integrin receptor drug, c7E3 Fab serves as a prototype for other anti-integrin receptor, and more generally, antiadhesion receptor, agents designed to treat and/or prevent human disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1994) · New England Journal of Medicine · doi:10.1056/nejm199404073301402 · Cited by 2,589
Initiation of Platelet Adhesion by Arrest onto Fibrinogen or Translocation on von Willebrand Factor
Savage, B., Saldívar, E., & Ruggeri, Z. M. (1996) · Cell · doi:10.1016/s0092-8674(00)80983-6 · Cited by 1,196
Topol, E., Califf, R., Weisman, H., Ellis, S., Tcheng, J., Worley, S., Ivanhoe, R., George, B., Fintel, D., Weston, M., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90007-8 · Cited by 838
The Fourth Stage of the Epidemiologic Transition: The Age of Delayed Degenerative Diseases
Olshansky, S. J., & Ault, A. B. (1986) · The Milbank Quarterly · doi:10.2307/3350025 · Cited by 820
Platelet Glycoprotein IIb/IIIa Receptors in Cardiovascular Medicine
Lefkovits, J., Plow, E. F., & Topol, E. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506083322306 · Cited by 754
Diacovo, T., Roth, S., Buccola, J., Bainton, D., & Springer, T. (1996) · Blood · doi:10.1182/blood.v88.1.146.146 · Cited by 537
Platelets and Thrombolytic Therapy
Coller, B. S. (1990) · New England Journal of Medicine · doi:10.1056/nejm199001043220107 · Cited by 482
Self-citationGoldsmith, H. L., & Turitto, V. T. (1986) · PubMed · Cited by 476
Reverter, J. C., Béguin, S., Kessels, H., Kumar, R., Hemker, H. C., & Coller, B. S. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118859 · Cited by 393
Self-citationPlatelet accumulation in experimental angioplasty: time course and relation to vascular injury.
Wilentz, J. R., Sanborn, T. A., Haudenschild, C. C., Valeri, C. R., Ryan, T. J., & Faxon, D. P. (1987) · Circulation · doi:10.1161/01.cir.75.3.636 · Cited by 294
Cited by
Hynes (2002) · doi:10.1016/s0092-8674(02)00971-6 · Cited by 8,606
The final steps of integrin activation: the end game
Shattil, S. J., Kim, C., & Ginsberg, M. H. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2871 · Cited by 1,086
Weitz, J. I., Eikelboom, J. W., & Samama, M. M. (2012) · Chest · doi:10.1378/chest.11-2294 · Cited by 527
Adams, R. A., Bauer, J., Flick, M. J., Sikorski, S. L., Nuriel, T., Lassmann, H., Degen, J. L., & Akassoglou, K. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20061931 · Cited by 335
Scheer, F. A. J. L., Michelson, A. D., Frelinger, A. L., Evoniuk, H., Kelly, E. E., McCarthy, M., Doamekpor, L. A., Barnard, M. R., & Shea, S. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024549 · Cited by 206
Metadata
- Authors
- Coller, B. S.
- Venue
- Journal of Clinical Investigation
- Published
- 1997-04-01
- Volume
- 99
- Issue
- 7
- Pages
- 1467-1471
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2080713469
- Cited by
- 263
- References
- 20
- FWCI
- 12.97
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics. https://app.cochat.ai/papers/10.1172/jci119307
- The paper
- Coller, B. S. (1997). Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics. Journal of Clinical Investigation. https://doi.org/10.1172/jci119307
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
